Our Services
Medical Information
Helpful Resources
Published on: 8/18/2026
Carrying two different ALPL variants, one inherited from each parent, is called compound heterozygosity, and it usually points to autosomal recessive hypophosphatasia (HPP), a condition in which low alkaline phosphatase activity impairs bone and tooth mineralization. Because the two variants can differ in severity and some exert a dominant negative effect, outcomes range widely, from perinatal or infantile bone disease to milder dental and joint symptoms that first appear in adulthood, and family members may be affected very differently. Several factors influence what your specific combination means, including variant type, enzyme activity levels, and family history, so see below to understand more before drawing conclusions.
If bone pain, frequent fractures, early tooth loss, muscle weakness, or fatigue are what brought you here, mapping your symptoms is a practical next step while you wait on genetic counseling or specialist care. Take a free, instant, online symptom check to see which conditions may explain what you are experiencing and how to prepare for your next appointment.
Last reviewed for medical accuracy: 08/18/2026
If you’ve been told you carry two different ALPL gene mutations, you may have questions about what that means for your health and how it might affect you or your family. This guide will explain:
By the end, you’ll have a clearer picture and know when to seek medical advice.
The ALPL gene provides instructions for making an enzyme called tissue non‐specific alkaline phosphatase (TNSALP). This enzyme is important for:
When TNSALP levels are low, mineral deposits don’t form normally, leading to a condition called hypophosphatasia (HPP), which can range from very mild to life‐threatening.
“Compound heterozygous” means you have two different variants (mutations) in the same gene—one inherited from each parent. For the ALPL gene, these variants might affect the enzyme to different degrees.
Together, they determine how much functional enzyme your body can make. This combination is known as compound heterozygous ALPL gene variants.
Each ALPL variant is classified by how much it disrupts TNSALP activity:
• Severe (null) mutations
– Little to no enzyme function
– Often linked to severe, early‐onset HPP
• Moderate (hypomorphic) mutations
– Partial loss of function
– Can cause milder, later‐onset forms
When you carry two different variants:
Hypophosphatasia can affect people of all ages. Signs vary widely:
• Perinatal (before or at birth)
– Poor bone mineralization
– Respiratory problems
• Infantile (first 6 months)
– Rickets‐like bone disease
– Failure to thrive
• Childhood
– Delayed walking
– Frequent fractures
– Dental issues (early tooth loss)
• Adult
– Stress fractures, low bone density
– Joint pain, osteomalacia
– Dental problems
Not everyone with compound heterozygous ALPL gene variants will have all these issues. Some people remain asymptomatic until triggered by stress on bones or teeth.
If your lab report mentions two ALPL variants:
Review variant classification
– Pathogenic (clearly disease‐causing)
– Likely pathogenic
– Variant of uncertain significance (VUS)
Estimate enzyme activity
– Specialists can predict how each variant impacts TNSALP
Correlate with your health
– A genetic counselor or metabolic specialist can match mutation data to your clinical picture
Key points:
Carrying two different ALPL mutations can change inheritance patterns and risk:
Autosomal recessive inheritance
– Classic HPP often requires two pathogenic variants (one on each allele).
– Each child of two carriers has a 25% chance of having HPP.
Variable severity
– Compound heterozygous combinations explain why some siblings have mild forms and others more severe.
Reproductive considerations
– Prospective parents may seek carrier testing.
– Prenatal or preimplantation genetic diagnosis is an option for some families.
There is no single “cure” for all forms of HPP, but treatments focus on supporting bone health and addressing symptoms:
• Enzyme replacement therapy
– Asfotase alfa is approved for moderate‐to‐severe HPP.
– Helps improve bone mineralization.
• Supportive care
– Physical therapy to maintain strength and mobility
– Dental care for early tooth loss and dental abnormalities
• Monitoring
– Regular bone density scans (DEXA)
– Blood tests for calcium, phosphate, and alkaline phosphatase levels
Close collaboration with an endocrinologist, metabolic specialist, or geneticist ensures personalized care.
While genetics set the stage, day-to-day choices help you stay as healthy as possible:
Nutrition
– Balanced diet rich in calcium and vitamin D (under medical guidance)
– Avoid high‐dose vitamin D unless prescribed
Safe exercise
– Low-impact activities (swimming, cycling) to strengthen muscles without stressing bones
– Avoid sudden, high-impact sports if you’ve had fractures
Dental hygiene
– Regular dental check‐ups
– Good oral hygiene to protect fragile teeth
If you notice any new or worsening signs—like unexplained bone pain, dental changes, or muscle weakness—you don’t have to wait. Consider a free, online symptom check, using the doctor approved Ubie Symptom Checker to help you decide if you need to see a specialist.
Always talk with your healthcare provider about:
Your doctor can interpret your specific genetic scenario and guide you to the right specialists.
Carrying compound heterozygous ALPL gene variants means you have two different ALPL mutations—one on each copy of the gene. Together, they influence how much functional enzyme your body makes and help explain the wide range of hypophosphatasia severity. With this knowledge, you can:
Remember: genetics is one piece of the puzzle. Regular medical follow-up ensures you stay on top of any changes in your health.
Speak to your doctor about any concerns, and never ignore symptoms that feel serious or life‐threatening. Your healthcare team is there to help you navigate the best path forward.
(References)
* Whyte MP. Hypophosphatasia - aetiology, nosology, pathogenesis, diagnosis and treatment. Nat Rev Endocrinol. 2016 Apr;12(4):233-46. doi: 10.1038/nrendo.2016.14. Epub 2016 Feb 19. PMID: 26893260.
* Kishnani PS, Rush ET, Arundel P, Bishop N, Dahir K, Fraser W, Harmatz P, Linglart A, Munns CF, Nunes ME, Saal HM, Seefried L, Ozono K. Monitoring guidance for patients with hypophosphatasia treated with asfotase alfa. Mol Genet Metab. 2017 Sep;122(1-2):4-17. doi: 10.1016/j.ymgme.2017.07.010. Epub 2017 Jul 25. PMID: 28888853.
* Mornet E. Hypophosphatasia. Metabolism. 2018 May;82:142-155. doi: 10.1016/j.metabol.2017.08.013. Epub 2017 Sep 20. PMID: 28939177.
* Del Angel G, Reynders J, Negron C, Steinbrecher T, Mornet E. Large-scale in vitro functional testing and novel variant scoring via protein modeling provide insights into alkaline phosphatase activity in hypophosphatasia. Hum Mutat. 2020 Jul;41(7):1250-1262. doi: 10.1002/humu.24010. Epub 2020 Mar 18. PMID: 32160374; PMCID: PMC7317754.
* Mornet E, Taillandier A, Domingues C, Dufour A, Benaloun E, Lavaud N, Wallon F, Rousseau N, Charle C, Guberto M, Muti C, Simon-Bouy B. Hypophosphatasia: a genetic-based nosology and new insights in genotype-phenotype correlation. Eur J Hum Genet. 2021 Feb;29(2):289-299. doi: 10.1038/s41431-020-00732-6. Epub 2020 Sep 24. PMID: 32973344; PMCID: PMC7868366.
* Fenn JS, Lorde N, Ward JM, Borovickova I. Hypophosphatasia. J Clin Pathol. 2021 Oct;74(10):635-640. doi: 10.1136/jclinpath-2021-207426. Epub 2021 Apr 30. PMID: 33931563.
* Tournis S, Yavropoulou MP, Polyzos SA, Doulgeraki A. Hypophosphatasia. J Clin Med. 2021 Dec 1;10(23). doi: 10.3390/jcm10235676. Epub 2021 Dec 1. PMID: 34884378; PMCID: PMC8658462.
* Riancho JA. Diagnostic Approach to Patients with Low Serum Alkaline Phosphatase. Calcif Tissue Int. 2023 Mar;112(3):289-296. doi: 10.1007/s00223-022-01039-y. Epub 2022 Nov 8. PMID: 36348061.
* Reis FS, Lazaretti-Castro M. Hypophosphatasia: from birth to adulthood. Arch Endocrinol Metab. 2023 May 25;67(5):e000626. doi: 10.20945/2359-3997000000626. PMID: 37249457; PMCID: PMC10665056.
* Khan AA, Brandi ML, Rush ET, Ali DS, Al-Alwani H, Almonaei K, Alsarraf F, Bacrot S, Dahir KM, Dandurand K, Deal C, Ferrari SL, Giusti F, Guyatt G, Hatcher E, Ing SW, Javaid MK, Khan S, Kocijan R, Linglart A, M'Hiri I, Marini F, Nunes ME, Rockman-Greenberg C, Roux C, Seefried L, Simmons JH, Starling SR, Ward LM, Yao L, Brignardello-Petersen R, Lewiecki EM. Hypophosphatasia diagnosis: current state of the art and proposed diagnostic criteria for children and adults. Osteoporos Int. 2024 Mar;35(3):431-438. doi: 10.1007/s00198-023-06844-1. Epub 2023 Nov 20. PMID: 37982857; PMCID: PMC10866785.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.